Buyer problem
Regulated teams want AI leverage, but uncontrolled agents create risk: unclear sources, unclear authority, weak evidence, hidden access, unclear reviewer responsibility, and no receipt trail.
Buyer packet
Controlled AI/cGMP Diagnostic
A fast, bounded way to test AI leverage in regulated work without pretending the agent owns the decision.
Objective
Map one workflow and determine where AI agents can safely prepare, organize, or draft work while preserving human approval and evidence.
Deliverables
- Workflow map.
- Risk and authority boundary.
- Source and evidence map.
- Human approval model.
- Receipt and QC model.
- Implementation recommendation.
Timeline
- Day 0: workflow selection.
- Day 1-2: source and evidence intake.
- Day 3-4: workflow, risk, and review model.
- Day 5: recommendation and next-step proposal.
Pricing
- Discovery: $500+.
- Diagnostic: $1,500-$2,500.
- Implementation sprint: $5,000-$15,000.
Exclusions
- No autonomous GMP decisions.
- No final GMP record creation.
- No unsupported validation promise.
- No hidden production access.
- No public checkout shortcut.
Acceptance criteria
The diagnostic is complete when the buyer has a clear go/no-go decision.
Workflow clarity
The workflow, bottleneck, and desired preparation task are clear.
Control clarity
The source, blocked actions, approval points, and evidence trail are clear.
Risk clarity
Known risks and project-specific validation needs are explicit.
Next step
The buyer can approve discovery, diagnostic, sprint, or hold with confidence.